Travere Therapeutics (TVTX) PT Raised to $23 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Price: $50.57 -0.53%
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 30 | New: 16
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 30 | New: 16
Join SI Premium – FREE
Stifel analyst Alex Thompson raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $23.00 (from $22.00) while maintaining a Hold rating.
You May Also Be Interested In
- Whitbread PLC. (WTB:LN) (WTBCF) PT Raised to GBP32 at Morgan Stanley
- Boeing (BA) PT Lowered to $240 at Freedom Broker
- Baxter International (BAX) PT Lowered to $25 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
